



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

## \*CORRESPONDENCE

Magdalena Więdocha  
✉ mgdwiedocho@gmail.com

RECEIVED 07 October 2024

ACCEPTED 08 October 2024

PUBLISHED 28 October 2024

## CITATION

Więdocha M, Marcinowicz P, Komarnicki J, Tobiaszewska M, Dębowska W, Dębowska M and Szulc A (2024) Corrigendum: Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst? *Front. Psychiatry* 15:1507504. doi: 10.3389/fpsy.2024.1507504

## COPYRIGHT

© 2024 Więdocha, Marcinowicz, Komarnicki, Tobiaszewska, Dębowska, Dębowska and Szulc. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?

Magdalena Więdocha<sup>1,2\*</sup>, Piotr Marcinowicz<sup>1,2</sup>,  
Jan Komarnicki<sup>3</sup>, Małgorzata Tobiaszewska<sup>4</sup>,  
Weronika Dębowska<sup>1</sup>, Marta Dębowska<sup>1</sup> and Agata Szulc<sup>1,5</sup>

<sup>1</sup>Department of Psychiatry, Faculty of Health Sciences, Medical University of Warsaw, Pruszkow, Masovian, Poland, <sup>2</sup>KeyClinic, Warsaw, Poland, <sup>3</sup>Leszek Giec Upper-Silesian Medical Centre of the Medical University of Silesia, Katowice, Poland, <sup>4</sup>Medical University of Warsaw, Warsaw, Masovian, Poland, <sup>5</sup>MindHealth, Warsaw, Poland

## KEYWORDS

ketamine, esketamine, depression, treatment resistant depression (TRD), borderline personality disorder, ketamine-assisted psychotherapy (KAT)

## A Corrigendum on

### Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?

By Więdocha M, Marcinowicz P, Komarnicki J, Tobiaszewska M, Dębowska W, Dębowska M and Szulc A (2024) *Front. Psychiatry* 15:1398859. doi: 10.3389/fpsy.2024.1398859

In the published article, there was an error in the affiliations for authors Magdalena Więdocha, Piotr Marcinowicz and Agata Szulc. Two affiliations were not disclosed. Authors MW and PM were employed by KeyClinic. Author AS was employed by Mindhealth.

In the published article, there was an error in the **Conflict of Interest** statement, which previously stated:

“The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”

The corrected statement appears below:

“Authors MW and PM were employed by the company KeyClinic, a commercial mental health center which provides ketamine treatment, as one of many services. Author AS was employed by the company MindHealth, a commercial psychiatric center. AS was also a member of Janssen Cilag Advisory Board and gave lectures for Janssen Cilag.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.